The Journal of Allergy and Clinical Immunology
Volume 117, Issue 2, Supplement 2 , Pages A5-A7, February 2006

Information for category 1 CME Credit

Article Outline

 

Credit can now be obtained, free for a limited time, by reading the review articles in this issue. Please note the following instructions.

Method of Physician Participation in Learning Process: The core material for these activities can be read in this issue of the Journal or online at the JACI Web site: www.jacionline.org. The accompanying tests may only be submitted online at www.jacionline.org. Fax or other copies will not be accepted.

Date of Original Release: February 2006. Credit may be obtained for these courses until January 31, 2008.

Copyright Statement: Copyright © 2006-2008. All rights reserved.

Overall Purpose/Goal: To provide excellent reviews on key aspects of allergic disease to those who research, treat, or manage allergic disease.

Target Audience: Physicians and researchers within the field of allergic disease.

Accreditation/Provider Statements and Credit Designation: The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AAAAI designates these educational activities for up to 1.0 hour per chapter in category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he or she actually spent in the educational activity.

Back to Article Outline

CME article 

“Overview of the human immune response” 

(page S430)

List of Design Committee Members: Author: David D. Chaplin, MD, PhD

Activity Objectives 


1.To gain an appreciation of the differences between the innate and the adaptive arms of the immune response, and an understanding of the ways in which these 2 effector pathways cooperate for effective host immunity.

2.To understand basic principles of self-/nonself-discrimination in both the innate and the adaptive arms of the immune response.

3.To be familiar with key effector pathways of the innate immune response, including Toll-like receptors, natural killer cells and natural killer T cells, the complement system, and the signals controlling leukocyte adhesion and recruitment to damaged tissues.

Recognition of Commercial Support: This CME activity has not received external commercial support.

Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: David D. Chaplin has consultant agreements with Pfizer.

Back to Article Outline

CME article 

“Update on primary immunodeficiency diseases” 

(page S435)

List of Design Committee Members: Authors: Francisco A. Bonilla, MD, PhD, and Raif S. Geha, MD

Activity Objectives 


1.To know the principal clinical manifestations of common variable immunodeficiency and that transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) mutations occur in a significant subset of these patients.

2.To know that the clinical susceptibility to serious infection is rare in the majority of patients with DiGeorge syndrome due to 22q11 deletion.

3.To know that the activation-induced cytidine deaminase (AID) enzyme is expressed only in B cells and that its absence does not impact T-cell function.

4.To know that routine laboratory screening measures of immune function may not detect some important immunodeficiencies (eg, IL-1 receptor associated kinase [IRAK-4] deficiency).

Recognition of Commercial Support: This CME activity has not received external commercial support.

Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: Francisco A. Bonilla and Raif S. Geha have no significant relationships to disclose.

Back to Article Outline

CME article 

“Cytokines and chemokines” 

(page S441)

List of Design Committee Members: Authors: John W. Steinke, PhD, and Larry Borish, MD

Activity Objectives 


1.To provide an update on the advances of cytokines and chemokines in relation to asthma/allergy since the previous release of the Primer with particular attention to the IL-10 superfamily, IL-17 family, and newly discovered cytokines.

2.To discuss the development of the various families of regulatory T cells and their impact on preventing and dampening the immune response and the cytokines involved.

Recognition of Commercial Support: This CME activity has not received external commercial support.

Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: John W. Steinke and Larry Borish have no significant relationships to disclose.

Back to Article Outline

CME article 

“Autoimmunity, vasculitis, and autoantibodies” 

(page S445)

List of Design Committee Members: Authors: Susan J. Lee, MD, and Arthur Kavanaugh, MD

Activity Objectives 


1.To understand the immunopathophysiology of common rheumatic conditions.

2.To describe characteristic features of autoimmune diseases.

3.To be familiar with the treatment approaches to autoimmune diseases.

Recognition of Commercial Support: This CME activity has not received external commercial support.

Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: Susan J. Lee and Arthur Kavanaugh have no significant relationships to disclose.

Back to Article Outline

CME article 

“IgE, mast cells, basophils, and eosinophils” 

(page S450)

List of Design Committee Members: Authors: Calmin Prussin, MD, and Dean D. Metcalfe, MD

Activity Objectives 


1.To understand the physiology of IgE and IgE receptor bearing cells (mast cells and basophils) and each component's respective contribution to allergic disease pathogenesis.

2.To understand eosinophil physiology and the contribution of eosinophils to disease pathogenesis.

3.To understand potential future therapeutic approaches by targeting the above inflammatory cell lineages.

Recognition of Commercial Support: This CME activity has not received external commercial support.

Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: Calman Prussin and Dean D. Metcalfe have no significant relationships to disclose.

Back to Article Outline

CME article 

“Asthma: Factors underlying inception, exacerbation, and disease progression” 

(page S456)

List of Design Committee Members: Authors: Robert F. Lemanske, Jr, MD, and William W. Busse, MD

Activity Objectives 


1.To describe the concept of impairment and risk domains as they apply to asthma severity and control.

2.To understand factors that may be implicated in asthma inception, asthma exacerbation, or both.

3.To describe factors that may contribute to disease progression in asthma.

Recognition of Commercial Support: This CME activity has not received external commercial support.

Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: Robert F. Lemanske, Jr, has consultant arrangements with Aventis, AstraZeneca, and GlaxoSmithKline. William W. Busse has no significant relationships to disclose.

Back to Article Outline

CME article 

“Control of allergic airway inflammation through immunomodulation” 

(page S461)

List of Design Committee Members: Authors: David B. Corry, MD, and Farrah Kheradmand, MD

Activity Objectives 


1.To understand the immunologic basis of allergic asthma.

2.To understand the new immunomodulatory therapeutic approaches that are being tested in asthma.

3.To understand which immunomodulatory therapies have been approved by the US Food and Drug Administration for the therapy of asthma.

Recognition of Commercial Support: This CME activity has not received external commercial support.

Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: David B. Corry and Farrah Kheradmand have no significant relationships to disclose.

Back to Article Outline

CME article 

“Drug allergy” 

(page S464)

List of Design Committee Members: Author: Paul A. Greenberger, MD

Activity Objectives 


1.To review the allergic-like and other immunologic adverse effects of immunomodulatory therapies.

2.To identify high, moderate, and lower risk situations for readministration of incriminated medications to patients with drug allergies.

3.To learn immunologic explanations for Stevens-Johnson syndrome and toxic epidermal necrolysis.

Recognition of Commercial Support: This CME activity has not received external commercial support.

Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: Paul A. Greenberger has no significant relationships to disclose.

Back to Article Outline

CME article 

“Food allergy” 

(page S470)

List of Design Committee Members: Authors: Scott H. Sicherer, MD, and Hugh A. Sampson, MD

Activity Objectives 


1.To understand the pathophysiology and clinical manifestations of food allergic disorders.

2.To appreciate the use and limitation of diagnostic tests for food allergy.

3.To be familiar with current management and research efforts toward improved treatment of food allergy.

Recognition of Commercial Support: This CME activity has not received external commercial support.

Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: Scott H. Sicherer and Hugh A. Sampson have no significant relationships to disclose.

Back to Article Outline

CME article 

“Atopic dermatitis” 

(page S475)

List of Design Committee Members: Authors: Mark Boguniewicz, MD, and Donald Y. M. Leung, MD, PhD

Activity Objectives 


1.To recognize the immunoregulatory role of IL-10 in both extrinsic and intrinsic atopic dermatitis.

2.To discuss the benefit of early treatment with topical calcineurin inhibitors to decrease eczema flares and need for topical steroid rescue.

Recognition of Commercial Support: This CME activity has not received external commercial support.

Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: Mark Boguniewicz has received grants from Astellas and Novartis and is a lecture honoraria for Astellas and Novartis. Donald Y. M. Leung has a consultant arrangement with Novartis and is on the speaker's bureau for Novartis and Astellas.

PII: S0091-6749(06)00162-X

doi:10.1016/S0091-6749(06)00162-X

The Journal of Allergy and Clinical Immunology
Volume 117, Issue 2, Supplement 2 , Pages A5-A7, February 2006

Article Tools